tbuckley/cabot-search huggingface dataset:
Significance of Asplenia in Recognition of Inoperable Congenital Heart Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE TOTAL AMOUNT OF CIRCULATING SUGAR IN THE BLOOD
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Malignant Hyperthermia
Authors: Eugene H. Flewellen
Journal: JAMA (1976)

<h3>To the Editor.—</h3> I believe that the MEDICAL NEWS report on malignant hyperpyrexia (235:238, 1976) did not bring out the most important point relating to this often fatal syndrome. The morbidity and mortality of malignant hyperpyrexia is directly related to how soon the diagnosis is made and therapy begun after the temperature begins to climb. It is becoming mandatory, I believe, for all patients undergoing general anesthesia and those receiving amide local anesthetics, to have the temperature monitored continuously in the operating room. Failure to do so, in the event that the syndrome occurs and is not diagnosed until the temperature has risen to the high levels, may contribute substantially to the patient's death.
“Umeclidinium in patients with COPD: a randomised, placebo-controlled study.” Roopa Trivedi, Nathalie Richard, Rashmi Mehta and Alison Church.<i>Eur Respir J</i>2014; 43: 72–81.
Journal: European Respiratory Journal (2014)

Unfortunately the interpretation of the transitional dyspnoea index (TDI) score data at day 84 was incorrect for the umeclidinium 62.5 mg dose in the abstract and body of the text in this article.It was stated that improvements in the least squares mean TDI focal score for the umeclidinium 62.5 mg dose, compared with placebo, was significant; however, because p50.05 (as opposed to p,0.05), the improvement was not significant.The corrected abstract (paragraph 3, penultimate sentence) should read: ''Significant improvements in least squares mean transitional dyspnoea index focal score for UMEC 125 mg (1.3 units; p,0.05) and change from baseline St George's Respiratory Questionnaire total score for both UMEC doses (-7.9 and -10.87 units, for UMEC 62.5 mg and 125 mg, respectively; both p,0.001) were noted compared with placebo at week 12.''The corrected second and third sentences in the ''Results: Dyspnoea and rescue medication use'' section should read: ''Patients receiving UMEC demonstrated statistically significant improvements in LSM TDI focal score compared with placebo at all time points except for UMEC 62.5 mg at day 84 (fig.4).At day 84, both UMEC doses demonstrated improvements in LSM TDI focal score compared with placebo which met the minimal clinically important difference (MCID) for the TDI [17] (1.0, 95% CI 0.0-2.0,p50.05 for UMEC 62.5 mg; and 1.3, 95% CI 0.3-2.3,p,0.05 for UMEC 125 mg).''
Analgesic nephropathy in 1981: which drug is responsible?
Authors: M. Goldberg
Journal: JAMA (1982)

In 1953, Spühler and Zollinger from Switzerland described a group of patients with chronic interstitial nephritis in whom there appeared to be an association between the renal disease and the ingestion of large quantities of certain analgesic drugs. This report was followed by several others from other countries in Europe and, ultimately, from South Africa, Australasia, and North America supporting this proposed drug-disease association. In the 1950s and 1960s there raged in the literature (also manifest at international medical congresses) debate and controversy concerning the possible relationships between "over-the-counter" pain-relieving medication and kidney disease. The major issues under discussion were (1) Was there, indeed, a causal relationship between analgesic drugs and renal disease, or was there merely a coincidental association between certain types of renal disease and the desire to consume analgesics (eg, some proposed that the renal disease was no different from chronic bacterial pyelonephritis)? (2) If there was
Second-Opinion Trial in Patients Recommended for Coronary Angiography
Authors: Mark A. Milchak
Journal: JAMA (1993)

<h3>To the Editor.</h3> —I read with interest the article by Graboys et al.<sup>1</sup>I find their data interesting; however, their conclusions are quite bothersome. The suggestion that 50% of the catheterizations performed in the United States are unjustified is simply not supported by the data. Several points should be emphasized. The study involved only 171 patients at an institution that must certainly have performed several thousand catheterizations over the 7 years included in the study. The fact that the initial recommendation for the procedure generated enough patient anxiety that a second opinion was sought leads me to believe that there was a high degree of inappropriate test ordering in the sample group. The study patients therefore do not constitute an adequate sampling of patients undergoing cardiac catheterization. The clinical course of the patients studied was not completely benign since it included 11 deaths and 19 new infarctions. In the
What's new in the other general journals
Authors: Alison Tonks
Journal: BMJ (2006)

Pacemakers and implantable cardioverter defibrillators save lives—but only when they work. Although millions of people have these devices, it's hard to say accurately how often they fail and how often the patient's life is at risk when they do. All we know is that malfunction is not a rare event. Credit: JAMA After appraising two new papers on the subject (pp 1901-6 and 1929-34), one commentator estimates that about seven in every 1000 pacemakers and about 21 in every 1000 cardioverter defibrillators malfunction badly enough to need replacing. Neither of these estimates included devices that broke down because of faulty leads. Nor did the estimates include people who died as a result of their device malfunctioning. Unreliable reporting means that both estimates are likely to be lower than the real rate, which, for pacemakers at least, seems to be going down. The trend for cardioverter defibrillators looks less predictable. Credit: JAMA Information on the safety of these devices is a complex mosaic, the author writes, and many of the pieces are still missing. What, for example, should doctors do when regulators issue a safety warning about a particular model? In a third paper (pp 1907-11), doctors from Canada electively replaced the “faulty” cardioverter defibrillator in about a fifth of their patients, although some replaced none and others replaced 45% (24/53). In 6% (31/533) of patients, the elective replacement caused serious surgical complications, most commonly bleeding and infections. Two patients died. JAMA2006;295: 1944–6 [OpenUrl][1][CrossRef][2][PubMed][3] Poor US women often miss out on recommended cancer screening services. In an attempt to reach them, researchers trained “prevention coaches” to telephone and motivate women to keep up to date with their cervical screening, mammography, and colorectal cancer screening. The coaches used a partially scripted interview technique to find out why women weren't attending and how any barriers to … [1]: {openurl}?query=rft.jtitle%253DJAMA%26rft.stitle%253DJAMA%26rft.issn%253D0002-9955%26rft.aulast%253DWilkoff%26rft.auinit1%253DB.%2BL.%26rft.volume%253D295%26rft.issue%253D16%26rft.spage%253D1944%26rft.epage%253D1946%26rft.atitle%253DPacemaker%2Band%2BICD%2Bmalfunction--an%2Bincomplete%2Bpicture.%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.295.16.1944%26rft_id%253Dinfo%253Apmid%252F16639055%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1001/jama.295.16.1944&link_type=DOI [3]: /lookup/external-ref?access_num=16639055&link_type=MED&atom=%2Fbmj%2F332%2F7549%2F1084.atom
Science and Policy in Regulatory Decision Making: Getting the Facts Right about Hazardous Air Pollutants
Authors: Ken Sexton
Journal: Environmental Health Perspectives (1995)

Hazardous air pollutants are regulated under Title IlIl of the 1990 Clean Air Act Amendments.The Amendments replace the risk-based approach mandated in the 1977 Amendments with a prescriptive, technology-based approach requiring that maximum achievable control technology (MACT) be applied to all major industrial sources of 189 hazardous air pollutants.The change reflects political, rather than scientific consensus that the public health benefits justify the costs.The choice is put into perspective by looking at the interface between science and policy that occurs as part of regular decisionmaking.Particular emphasis is given to examining the interrelationships among facts (science), judgments (science policy), and policy (values) in the context of the risk assessment paradigm.Science and policy are discussed in relation to Title l1l, contrasting the political consensus for action with the scientific uncertainty about risks and benefits.It is argued that a balanced research program is needed to get the facts right about hazardous air pollutants, including research to meet statutory requirements, to reduce uncertainties in risk assessment, and to address strategic
Cesarean section rates in the United States. The short-term failure of the National Consensus Development Conference in 1980
Authors: N. Gleicher
Journal: JAMA (1984)

The magnitude of cesarean section rates in the United States has been of increasing public concern. A consensus development conference in 1980 formulated recommendations that were expected to lead to a decrease in national cesarean section rates. A review of cesarean section patterns for the last five years in many representative states revealed, contrary to expectations, a continuing increase in cesarean section delivery rates even after the conference. A review of underlying causes for these developments suggests that only a more efficient peer review process, involving individual physicians as well as institutions, will lead to a decline of unacceptably high cesarean section rates in this country. (<i>JAMA</i>1984;252:3273-3276)
Insanity defense in criminal trials and limitation of psychiatric testimony. Report of the Board of Trustees
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Front &amp; Back Matter
Authors: Per Bech, Andrea W.M. Evers, Uwe Gieler, Monika I. Hasenbring, Henriët van Middendorp, Giovanni A. Fava, Silvana Grandi, Jenny Guidi, Gregor Hasler, Fiammetta Cosci, Carlo Marchesi, Paolo Ossola, Francesca Scagnelli, Francesca Paglia, Sonja Aprile, Alberto Monici, Matteo Tonna, Giulio Conte, Franco Masini, Chiara De Panfilis, Diego Ardissino, Ueli Kramer, Stéphane Kolly, Laurent Berthoud, Sabine Keller, Martin Preisig, Franz Caspar, Thomas Berger, Yves de Roten, Pierre Marquet, Jean-Nicolas Despland, Allan A. Abbass, Sarah J. Nowoweiski, Denise Bernier, Robert Tarzwell, Manfred E. Beutel, Ajandek Eory, Sandor Rozsa, Peter Torzsa, Laszlo Kalabay, Xenia Gonda, Zoltan Rihmer, K. Barnicot, M. Savill, N. Bhatti, S. Priebe, Glen I. Spielmans, Katherine Gerwig, Ulrich Voderholzer, Nirmal Herbst, Nicola Thiel, Ronja Schaub, Christine Knaevelsrud, Silke Stracke, Elisabeth Hertenstein, Christoph Nissen, Anne Katrin Külz, Johannes C. Ehrenthal, Ulrike Dinger, Ottilia Klipsch, Johanna Köhling, Christoph Nikendei, Wolfgang Herzog, Henning Schauenburg, Satz Mengensatzproduktion, Druckerei Stückle, Druckerei Stückle
Journal: Psychotherapy and Psychosomatics (2014)
Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases
Authors: Ayalew Tefferi, Naseema Gangat, Rakhee Vaidya, Kebede Begna, Curtis A. Hanson, Daniel L. Van Dyke, Domenica Caramazza, Animesh Pardanani
Journal: Blood (2011)
Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia
Authors: R. T. Paasuke
Journal: JAMA (1986)

One hundred thirty-one patients who were referred for muscle biopsy for in vitro contracture testing (IVCT) for susceptibility to malignant hyperthermia (MH) were studied. Serum creatine kinase (CK) levels were determined routinely before biopsy by the hospital clinical laboratories. Thirty-four had abnormal IVCTs (indicating susceptibility to MH) and 87 patients had normal IVCTs; all these 121 patients had normal CK levels. Ten additional patients had other muscle disorders (central core disease, hyperkalemic periodic paralysis, and Duchenne's muscular dystrophy) and abnormal IVCTs; six of the ten had elevated CK levels. We conclude that the serum CK level, as determined routinely, does not identify MH-susceptible individuals, but may indicate the presence of muscle disease. Therefore, the use of serum CK level as a screening or diagnostic test for susceptibility to MH should be abandoned. (<i>JAMA</i>1986;255:769-771)
Ditiocarb sodium and HIV infection
Journal: JAMA (1991)

<h3>To the Editor.</h3> —The recent update of the cardiopulmonary resuscitation guidelines<sup>1</sup>and editorial comment<sup>2</sup>are welcome as further developments in this complicated and evolving area. However, many specific problems were not addressed. Truog<sup>3</sup>reviewed the question of the status of DNR orders in patients undergoing surgery and anesthesia. For anesthesiologists, there are special and frequently conflicting aspects of providing care during palliative surgery. The following case highlights this dilemma: A 54-year-old man with endstage amyotrophic lateral sclerosis presented for gastrostomy. He was fully alert but confined to a wheelchair. He lived at home with his caring wife. His profound weakness did not permit coordinated swallowing, and his decline was being accelerated by malnutrition. Respiratory reserve was negligible with PaO<sub>2</sub>of 56 mm Hg breathing air and PaCO<sub>2</sub>of 54 mm Hg. In a discussion prior to the procedure, the patient and his wife revealed an
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study
Authors: J. Ena
Journal: JAMA (1993)

<h3>Objectives.</h3> —To examine the trends of intravenous vancomycin usage during a 10-year period, to classify the indications for which physicians prescribed the antibiotic, and to identify the independent predictors for empirical use of vancomycin. <h3>Design.</h3> —A descriptive epidemiological study, a cross-sectional study, and a case-control study were performed. <h3>Setting.</h3> —A 900-bed university-teaching hospital. <h3>Main Outcome Measures.</h3> —The annual crude usage (grams) and incidence density (grams/1000 patient-days) of vancomycin were measured for 10 years (July 1981 to July 1991). In 109 randomly selected patient medical records, we evaluated the proportion of usage of vancomycin classified as prophylaxis, empirical therapy, or specifically directed therapy. Univariate and multivariate analyses were performed to identify determinants of empirical administration of vancomycin vs a penicillase-resistant penicillin to 64 case patients and 64 control patients. <h3>Results.</h3> —The rate of vancomycin usage increased 20-fold from 5.72 g/1000 patient-days in 1981 to 121.25 g/1000 patient-days in 1991. The use of vancomycin was significantly higher (<i>P</i>&lt;.0001) in hematology-oncology areas compared with that in other hospital areas. The rates for each indication for vancomycin were 35.0% for prophylaxis, 31.8% for empirical therapy, and 33.2% for therapy specifically directed by culture results. In a multivariate analysis, the presence of "plastic" medical devices was the best independent predictor for patients receiving vancomycin: intravenous lines (odds ratio [OR], 6.23; 95% confidence interval [CI], 2.28 to 17.06;<i>P</i>&lt;.001), Hickman catheters (OR, 76.12; 95% CI, 15.06 to 384.73;<i>P</i>&lt;.001), and other medical devices (OR, 10.50; 95% CI, 2.54 to 43.38;<i>P</i>=.001). <h3>Conclusions.</h3> —Vancomycin use has increased linearly in the last decade primarily related to the presence of indwelling vascular devices in hematology-oncology patients. Use of vancomycin is equally divided among empirical therapy, prophylaxis, and specific therapy for a documented infection. (<i>JAMA</i>. 1993;269:598-602)
p-Benzoquinone, a reactive metabolite of benzene, prevents the processing of pre-interleukins-1 alpha and -1 beta to active cytokines by inhibition of the processing enzymes, calpain, and interleukin-1 beta converting enzyme.
Authors: G F Kalf, J F Renz, R Niculescu
Journal: Environmental Health Perspectives (1996)

Chronic exposure of humans of benzene affects hematopoietic stem and progenitor cells and leads to aplastic anemia. The stromal macrophage, a target of benzene toxicity, secretes interleukin-1 (IL-1), which induces the stromal fibroblast to synthesize hematopoietic colony-stimulating factors. In a mouse model, benzene causes an acute marrow hypocellularity that can be prevented by the concomitant administration of IL-1 alpha. The ability of benzene to interfere with the production and secretion of IL-1 alpha was tested. Stromal macrophages from benzene-treated mice were capable of the transcription to the IL-1 alpha gene and the translation of the message but showed an inability to process the 34-kDa pre-IL-1 alpha precursor to the 17-kDa biologically active cytokine. Treatment of normal murine stromal macrophages in culture with hydroquinone (HQ) also showed an inhibition in processing of pre-IL-1 alpha. Hydroquinone is oxidized by a peroxidase-mediated reaction in the stromal macrophage to p-benzoquinone, which interacts with the sulfhydryl (SH) groups of proteins and was shown to completely inhibit the activity of calpain, the SH-dependent protease that cleaves pre-IL-1 alpha. In a similar manner, HQ, via peroxidase oxidation to p-benzoquinone, was capable of preventing the IL-1 beta autocrine stimulation of growth of human B1 myeloid tumor cells by preventing the processing of pre-IL-1 beta to mature cytokine. Benzoquinone was also shown to completely inhibit the ability of the SH-dependent IL-1 beta converting enzyme. Thus benzene-induced bone marrow hypocellularity may result from apoptosis of hematopoietic progenitor cells brought about by lack of essential cytokines and deficient IL-1 alpha production subsequent to the inhibition of calpain by p-benzoquinone and the prevention of pre-IL-1 processing.
Coming in December 22 issue of JAMA: Drug Identification Guide
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal